Bernstein Upgrades Amgen (AMGN) to Outperform
More News related to AMGN
- New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
- Amgen Highlights Data to be Presented at ASH
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
- Amgen to Present at Lazard Capital Healthcare Conference
More News related to Upgrades
- Broadpoint.AmTech Reiterates a 'Buy' on Marvell Technology (MRVL); Raises Estimates & PT
- Unemployment Data Brings Hope: Art Hogan Weighs In
- Brean Murray Maintains a 'Buy' on athenahealth (ATHN); Lofty Valuation Surpassed Only by Lofty Goals
- Benchmark Raises American Tower's (AMT) Price Target to $50 on Strong Tower Demand
- Benchmark Increases Crown Castle's (CCI) Price Target to $45 on Clearwire (CLWR) Exposure
Sanford C. Bernstein upgrades Amgen (Nasdaq: AMGN) from Market Perform to Outperform.
For more analyst ratings on AMGN click here.
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
UpgradesStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
